GeoVax Labs, Inc. (GOVX) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in GeoVax Labs (GOVX) by buying shares or fractional shares at any major US broker, through a small-cap or biotech ETF that happens to hold it, or as one speculative holding in a thematic basket. GeoVax is a small, clinical-stage biotechnology company developing vaccines and immunotherapies, led by GEO-CM04S1 (a next-generation COVID-19 vaccine in Phase 2 trials aimed at immunocompromised patients), Gedeptin (a gene-directed oncology therapy for head and neck cancer), and GEO-MVA (an Mpox and smallpox vaccine). The single most important thing to understand is that this is a pre-revenue, cash-burning micro-cap whose value rests on binary clinical and regulatory outcomes, not on current sales, so it carries extreme risk and has repeatedly raised money by issuing shares.
GOVX stock price
As of 2026-07-14, GeoVax Labs, Inc. (GOVX) last closed at $1.07, down 93.8% over the past year. Over the past 52 weeks it has traded between $1.05 and $21.27.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or GeoVax Labs, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does GeoVax Labs, Inc. (GOVX) do?
GeoVax Labs, Inc. is a small, clinical-stage biotechnology company (listed on Nasdaq) that develops vaccines and immunotherapies using its Modified Vaccinia Ankara (MVA) viral-vector platform and a separate gene-directed cancer therapy. It is pre-revenue in the commercial sense: its value is tied to whether its experimental programs succeed in trials and eventually reach the market, not to product sales today.
The pipeline has three main pillars. GEO-CM04S1 is the lead program, a next-generation COVID-19 vaccine being studied in Phase 2 trials as a primary vaccine for immunocompromised patients (such as those with blood cancers), as a booster in chronic lymphocytic leukemia patients, and as a more durable booster for people who previously received mRNA vaccines. Gedeptin is a gene-directed oncolytic therapy that completed a Phase 1/2 trial in advanced head and neck cancer, with a Phase 2 combination trial alongside an immune checkpoint inhibitor planned; it holds Orphan Drug Designation for oral and pharyngeal cancers. GEO-MVA targets Mpox and smallpox.
The financial picture is the dominant story. GeoVax reported large net losses (roughly $21.5 million in 2025), held only a few million dollars in cash, and its auditors issued a going-concern opinion, with cash projected to fund operations only into mid-2026 before further raises. The company has repeatedly issued stock and warrants (including PIPE deals and warrant-exercise inducements in 2026) to stay funded, which dilutes existing shareholders. This makes GOVX a classic high-risk, event-driven micro-cap biotech.
What's driving GeoVax Labs, Inc. (GOVX)?
1. GEO-CM04S1 in immunocompromised patients
The lead value driver is GEO-CM04S1, a next-generation COVID-19 vaccine in three Phase 2 trials, positioned for immunocompromised populations (such as hematologic-cancer and CLL patients) who often respond poorly to standard mRNA vaccines. GeoVax frames this as a large unmet medical need. Positive, differentiated data in that niche is the clearest catalyst that could re-rate the stock, though clinical success is far from guaranteed.
2. Gedeptin oncology program
Gedeptin is a gene-directed oncolytic therapy that completed a Phase 1/2 trial in advanced head and neck cancer, with a planned Phase 2 study combining it with an immune checkpoint inhibitor in first recurrent disease. It carries Orphan Drug Designation for oral and pharyngeal cancers, which can bring development incentives. Any encouraging combination data would add a second, independent shot on goal beyond the COVID vaccine.
3. GEO-MVA and biodefense optionality
GEO-MVA targets Mpox and smallpox, tapping into government and biodefense interest in stockpiled vaccines and the MVA platform's established safety profile. Public-health demand and potential government funding or contracts could provide non-dilutive support. This program is earlier and less certain than the lead assets but broadens the platform story beyond a single indication.
4. Funding, partnerships, and non-dilutive capital
Because GeoVax burns cash and has a short runway, its near-term trajectory depends heavily on raising money on acceptable terms: grants, government contracts, strategic partnerships, or licensing deals would be far better for shareholders than repeated dilutive stock and warrant offerings. Landing non-dilutive funding or a partner would validate the platform and reduce the constant overhang from equity raises.
What are the risks to GeoVax Labs, Inc. (GOVX)?
The risks here are severe and existential. GeoVax has essentially no product revenue, posts large ongoing losses, and its auditors issued a going-concern opinion with cash projected to last only into mid-2026 absent new financing, so survival itself is a risk. To stay funded it has repeatedly issued stock, warrants, and PIPE deals, heavily diluting existing holders and pressuring the share price. Its programs are all clinical-stage, meaning any could fail in trials, miss endpoints, or stall at regulators, which for a single-catalyst micro-cap can be devastating. As a low-priced Nasdaq small-cap, the stock is thinly traded and highly volatile, exposed to potential listing or minimum-price issues, reverse splits, and sharp swings on any news. This is a speculative bet where total loss of capital is a realistic outcome.
How is GeoVax Labs, Inc. (GOVX) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see GeoVax Labs, Inc.'s investor relations page or your broker.
- Revenue: Minimal / pre-commercial; no meaningful product sales (any revenue is grant or collaboration related)
- Profitability: Deeply unprofitable; net loss roughly $21 million in 2025 as R&D and trial spending continue
- Cash runway: Very tight; only a few million in cash and a going-concern opinion, funding operations into roughly mid-2026 before further raises
- Clinical stage: Phase 2 for lead COVID vaccine GEO-CM04S1; Phase 1/2 completed for Gedeptin with a Phase 2 planned; GEO-MVA earlier
- Dilution risk: High; repeated stock, warrant, and PIPE issuances in 2025-2026 to fund operations
- Market cap: Micro-cap (small tens of millions range); highly volatile and thinly traded
These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. For a pre-revenue biotech like GeoVax, traditional valuation multiples (P/E, price-to-sales) are not meaningful because there are no profits and little revenue. What matters instead is cash on hand, burn rate, dilution, and the odds attached to clinical and regulatory milestones, all of which can change quickly.
Who competes with GeoVax Labs, Inc. (GOVX)?
COVID-19 and vaccine developers
In the COVID and broader vaccine space, GeoVax's GEO-CM04S1 competes for attention and market with far larger, well-funded players such as Pfizer, Moderna, and Novavax. Those companies have approved products, huge cash reserves, and established manufacturing, so GeoVax's angle is a differentiated vector and a focus on immunocompromised patients rather than head-to-head scale.
Oncology and gene-directed therapy biotechs
Gedeptin competes in a crowded field of small and mid-cap oncology biotechs pursuing head and neck and other solid-tumor therapies, often in combination with checkpoint inhibitors from majors like Merck (Keytruda) and Bristol Myers Squibb. Success depends on differentiated data in specific indications rather than out-competing large pharma directly.
Other clinical-stage micro-cap biotechs
As a speculative, cash-constrained micro-cap, GOVX also effectively competes with the broad universe of small clinical-stage biotechs for scarce investor capital. These names trade on catalysts and sentiment, carry similar dilution and going-concern risks, and are an alternative way investors express high-risk bets on early drug development.
How to invest in GeoVax Labs, Inc. (GOVX)
There are three common ways to get GOVX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so GOVX sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where GOVX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on GeoVax Labs, Inc. (GOVX)
GeoVax is a speculative, clinical-stage biotech with no meaningful product revenue, a tight cash runway, going-concern warnings, and heavy dilution risk. It is a high-risk bet on trial data and regulatory outcomes for its vaccine and oncology programs, suitable only for money you can afford to lose entirely.
Build a basket around GOVX with Walnut
Use GeoVax Labs, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is GOVX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. GeoVax is a speculative, pre-revenue biotech with a going-concern warning, a short cash runway, and heavy dilution risk, so it is a high-risk bet on clinical and regulatory outcomes rather than a stable business. Some investors buy such names for asymmetric upside on trial data, but total loss of capital is a realistic outcome. Only consider money you can afford to lose.
What does GeoVax actually do?
+
GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies. Its lead programs are GEO-CM04S1, a next-generation COVID-19 vaccine in Phase 2 trials aimed at immunocompromised patients, Gedeptin, a gene-directed therapy for head and neck cancer, and GEO-MVA, an Mpox and smallpox vaccine. It does not yet sell approved products at scale, so it earns little to no product revenue today.
Why is GeoVax stock so volatile?
+
GOVX is a low-priced, thinly traded micro-cap whose value hinges on binary events: trial results, regulatory decisions, and funding announcements. With no steady revenue to anchor it, the stock can swing sharply on a single headline. Frequent capital raises and warrant issuances add dilution-driven pressure, and low liquidity magnifies moves in both directions.
Does GeoVax pay a dividend?
+
No. GeoVax is an unprofitable, cash-burning clinical-stage biotech that needs every dollar to fund research and trials, so it does not pay a dividend and is very unlikely to in the foreseeable future. Investors in a name like this are betting entirely on potential share-price appreciation from clinical success, not on income.
What are GeoVax's main clinical programs?
+
The three main programs are GEO-CM04S1 (a next-generation COVID-19 vaccine in Phase 2 trials, with a focus on immunocompromised patients), Gedeptin (a gene-directed oncolytic therapy that completed a Phase 1/2 trial in head and neck cancer, with a Phase 2 combination study planned), and GEO-MVA (a vaccine targeting Mpox and smallpox). Gedeptin holds Orphan Drug Designation for oral and pharyngeal cancers.
Can I get exposure to GOVX through an ETF?
+
GOVX may appear in some broad small-cap, micro-cap, or biotech index ETFs, but usually at a tiny weight given its very small market value. ETF exposure spreads single-stock risk across many holdings, which greatly dilutes how much any GeoVax move affects you. Always check a fund's holdings before assuming meaningful exposure to GOVX specifically.
What are the biggest risks of investing in GOVX?
+
The biggest risks are financial survival and dilution: a going-concern opinion, a short cash runway, and repeated share issuances that erode ownership. On top of that, every program is clinical-stage and could fail in trials or at regulators, and as a thinly traded micro-cap the stock is highly volatile and exposed to listing and reverse-split risk. For GOVX, a total loss of invested capital is a genuine possibility.
What is the going-concern warning about?
+
A going-concern opinion is a formal note from a company's auditors that there is substantial doubt about its ability to continue operating over the next year without raising more money. GeoVax has carried such a warning, with cash projected to fund operations only into roughly mid-2026 absent new financing. It signals that the company depends on continued capital raises to survive, which is a serious risk for shareholders.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with GeoVax Labs, Inc.'s investor relations page or your broker before making investment decisions.